DSA-positive Transplant Patients
Conditions
Interventions
First, a single dose of rituximab (375 mg/m2 body surface) was administered to the patients. And then, one cycle of bortezomib (1.3 mg/m2, days 1, 4, 8 and 11) was administered to the patients.
Sponsors
Transplantation Surgery, Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: DSA positive patients with MFI values greater than 3,000 by LABScreen Single Antigen test. Patients who are informed of this study and consent to participate it by writing.
Exclusion criteria
Exclusion criteria: Patients with current or recent severe systemic infections requiring treatment (systemic antibiotics, antivirals, or antifungals). Serious diarrhea, active ulcer or uncontrolled diabetes likely to interfere with participation in this clinical study. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Known history of allergy to rituximab or bortezomib. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. Female subject is pregnant or breast-feeding. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative conversion rate of cross-match test | — |
Countries
Japan
Contacts
Public ContactKentaro Ide
Hiroshima University Hospital Trasnplantation Surgery
Outcome results
None listed